Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts.

标题
Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts.
作者
关键词
-
出版物
AMERICAN JOURNAL OF CARDIOLOGY
Volume 103, Issue 5, Pages 735-741
出版商
Elsevier BV
发表日期
2009-01-13
DOI
10.1016/j.amjcard.2008.11.014

向作者/读者发起求助以获取更多资源

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started